242 results about "Potentiator" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of bleomycin or bleomycin analogues in preparation of an immunopotentiator. The invention also provides a pharmaceutical composition and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing cancers. The pharmaceutical composition comprises bleomycin, bleomycin analogues or a combination thereof and an anti-tumor immunotherapeutic agent.

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a water-in-oil-in-water adjuvant, a veterinary vaccine and a preparation method thereof.The water-in-oil-in-water adjuvant is prepared from, by weight, 0.5%-7.5% of a hydrophilic composite surfactant, 0.6%-9.8% of an oleophylic composite surfactant, 70%-85% of mineral oil and the balance water; and the mineral oil also comprises the following components in concentration: a reinforcing agent of 0.45-0.9 g / ml and a stabilizing agent of 2-6.9 g / L, wherein the water-in-oil-in-water adjuvant forms a gelatinous structure under the regulation of the stabilizer and is a non-Newtonian fluid of which the viscosity is not higher than 25cp; the adjuvant shows the non-flowing fluid characteristic through the stabilizer, the rheological property of the produced vaccine is enhanced, the stability of the vaccine is improved, on the premise that the hydrophilic surfactant and the oleophylic surfactant are balanced, the natural polymer enhancer is added, and on the premise that the adjuvant viscosity is reduced and granuloma side reaction is not prone to being generated, the stability of the vaccine is improved. Short-term immunity and long-term immunity can be induced at the same time, and the application of the water-in-oil-in-water adjuvant in the field of veterinary vaccines is expanded.

The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

The invention belongs to the technical field of biological medicine, and particularly relates to application of actinomycin D in preparation of a ctDNA detection sensitizer. The invention provides a ctDNA release method based on actinomycin D as an enhancer, which can significantly improve the release level of ctDNA in early small-volume tumors and tiny residual lesions, thereby improving the sensitivity and positive detection rate of liquid biopsy in MRD detection. Under an extremely low dosage, the ActD can generally promote a plurality of human tumor cells to release ctDNA under the condition of not causing obvious cell death, and has good biological safety and adaptability. The method is especially suitable for tiny, biological inert or anatomical position hidden focuses which are difficult to identify by iconography, namely blind area patient groups in disease monitoring, and has a wide clinical application prospect.

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations.

To provide the use of a CBR1 agonist as an adjuvant and an adjuvant composition.SOLUTION: A compound represented by formula (1): Wherein R represents a cyclopropyl group or a 2-chloroethyl group. The antibody induction-promoting agent contains a compound represented by general formula (I) as an active ingredient.SELECTED DRAWING: None

The application discloses a kind of composition with immunoregulation and anti-aging function and preparation method thereof, and core component is marine collagen peptide, fusion polypeptide CPF-1, targeting senescent cell monoclonal antibody mAb Senolix, five gallate acyl glucose (PGG) and Hericium erinaceus polysaccharide.Fusion polypeptide CPF-1 is designed by domain fusion strategy, with collagen binding, immune activation and antibacterial function;Monoclonal antibody mAb Senolix targets the surface antigen p16^(INK4a) of senescent cell, and removes senescent cell by ADCC effect.The composition significantly improves immune cell activity, promotes collagen synthesis and reduces chronic inflammation through the synergistic effect of multiple components, and shows excellent immunoregulation and anti-aging effect in in vitro cell model and immunosuppressed mouse model, and can be used for developing immune enhancer, anti-aging drug or functional food.

The present application relates to an atomization device, comprising a first atomization source for atomizing a non-water-absorbing target substrate, a second atomization source for atomizing a reinforcing agent containing a water-absorbing agent, an air outlet for outputting a mixed aerosol, a first air outlet channel communicating the first atomization source and the air outlet, and a second air outlet channel communicating the second atomization source and the air outlet. The first air outlet channel and the second air outlet channel have a junction. Since the reinforcing agent contains a water-absorbing agent, the generated mixed aerosol has water-absorbing property. Since the mixed aerosol has water-absorbing property, it has water-absorbing growth performance and water-absorbing deposition effect, thereby significantly improving the overall deposition and absorption efficiency of the non-water-absorbing target substrate in the human respiratory tract.

The invention belongs to the technical field of natural pharmaceutical chemistry and medical application, and discloses a quinolone antibiotic synergist and application thereof in preparation of a medicine for treating bacterial infection. The structural formula of the quinolone antibiotic synergist is shown in the specification. The quinolone antibiotic synergist can effectively inhibit the activity of a staphylococcus aureus efflux pump, and the survival rate of mice infected with staphylococcus aureus can be remarkably increased when the quinolone antibiotic synergist is combined with quinolone antibiotics for use.

The invention belongs to the technical field of chemiluminescence immunoassay, and particularly relates to application of a luminescence retarder in improving development quality of solid-phase membrane immunodetection. According to the invention, when the concentration of the delay agent is fixed, the time of luminescence starting delay and the concentration of the enzyme catalyst are in nonlinear negative correlation, that is, the delay time is obviously increased along with the reduction of the enzyme concentration. The nonlinear negative correlation is suitable for luminescent systems of different reinforcing agents. Benefited from the enzyme concentration dependent luminescence delay effect, the chemiluminescence liquid with the delay effect is used for improving the development quality of solid-phase membrane immunodetection for the first time, noise and background signals are suppressed, and the chemiluminescence liquid has wide application value in the aspect of solid-phase membrane immunodetection.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

The present invention describes the synthesis and biological evaluation of new substituted pyridine derivatives as foxj1 activity enhancers. In embodiments, novel pyridine derivatives were synthesized and the ability thereof to enhance foxj1 activity was evaluated. The novel pyridine derivatives synthesized in the present invention not only exhibited excellent activity but also exhibited excellent metabolic safety and pharmacokinetic profile in a Tg (foxj1: egfp) transgenic zebrafish animal model. In addition, the novel pyridine derivatives synthesized in the present invention enhanced cilia-promoting capability in a motile ciliated cell differentiation experiment in which mouse tracheal epithelial cells (mTECs) were isolated from the airways of mice and cultured by ALI. As a result, a series of foxj1 activity enhancers with substituted pyridine skeleton has the potential to be developed as preventive and therapeutic agents for respiratory diseases.

Disclosed herein, in some aspects, are methods of treating autoimmune diseases or conditions using TCR targeting molecules or cells expressing TCR targeting molecules. TCR targeting molecules can comprise a moiety that binds to a TCR variable beta chain (TCRBV) or a TCR variable alpha chain (TCRAV). TCR targeting molecules can further comprise one, two or all of: (ii) an immune cell engager; (iii) a cytokine inhibitor molecule; (iv) a cytotoxic agent; and / or (v) a death receptor signal enhancer. Additionally, disclosed herein, in some aspects, are nucleic acids encoding the same, and methods of producing the aforesaid molecules.

The invention belongs to the technical field of biomedical detection, and discloses a TAR DNA binding protein 43 detection method based on LC-MS / MS and application. The detection method comprises the following steps: taking a biological matrix to be detected, and filtering to obtain filtrate; adding an ion enhancer into the obtained filtrate, oscillating and incubating, adding a protein precipitant, and separating precipitated protein; adding trypsin into the precipitated protein, and incubating to obtain a sample containing a characteristic peptide fragment; and detecting the TAR DNA binding protein 43 in the sample by adopting liquid chromatography-triple quadrupole mass spectrometry. According to the method, the TDP-43 is specifically detected and quantified by adopting a liquid chromatography-tandem mass spectrometry technology, so that the excellent effects of efficiently detecting and accurately quantifying the TDP-43 and improving the detection sensitivity and stability are achieved. The method can be applied to the fields of in-vitro diagnosis of neurodegenerative diseases, pathological mechanism research and therapeutic drug development.

The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.

The application belongs to the technical field of medicine, and relates to a use of minocycline in preparation of an antitumor synergist. The minocycline, as the antitumor synergist, has a synergistic effect with 5-fluorouracil and gemcitabine, significantly enhances the curative effect of an antitumor drug, reduces the dosage of the antitumor drug, and reduces side effects of the antitumor drug on the body or damage of the antitumor drug to normal tissue cells.

A noninvasive ophthalmic formulation, comprising a chelator (such as EDTA and its salts), a transport enhancer (such as Methyl Sulfonyl Methane; MSM), a second polyoxyalkylene permeation enhancer such as propylene glycol capable of enhancing permeation through lipid-thickened ocular membranes, a thickening agent such as hydroxyethyl cellulose (HEC) and a surfactant such as polysorbate 80, is provided. The novel combination of the ingredients unexpectedly and beneficially reduces symptoms associated with early-stage, age-related cataracts. Methods for treating cataracts with compositions of the invention and measurement of improved visual function by measuring contrast sensitivity (CS) are provided.

The invention belongs to the technical field of medical dressings, and particularly relates to a gel dressing for relieving postoperative lymphedema of breast cancer and a preparation method thereof.The gel dressing is prepared from, by weight, 0.1-0.5 part of active medicine, 8-12 parts of modified matrix, 0.2-0.8 part of dopamine hydrochloride, 2 parts of dispersing agent and 0.5-1.5 parts of enhancer, menthol with functions of promoting infiltration and inducing diuresis to alleviate edema is used for modifying mussel mucoprotein with good biocompatibility, the crosslinking gelling property of the mussel mucoprotein is improved, meanwhile, along with hydrolysis breakage of covalent bonds, gel slowly collapses to release active drugs, and the active drugs and the menthol cooperate with each other, and the postoperative lymphedema of breast cancer is treated from various mechanism ways.

The invention belongs to the technical field of antibacterial synergists, and discloses application of ramoplanin as a colistin antibacterial synergist. The invention provides a treatment strategy for combined use of ramoplanin as a polymyxin drug sensitizer in treatment of gram-negative bacterial infection, and in a test of combined use of ramoplanin and colistin for detection of a bacterial sterilization curve and the integrity of a bacterial outer membrane, the concentration of the ramoplanin is low and is only 16 [mu] g / mL; in the aspect of the antibacterial effect, the FICI index is relatively low, and after the ramoplanin and the colistin are jointly used, the MIC (Minimum Inhibitory Concentration) of the colistin can be reduced by 16 times at most. The research shows that ramoplanin is a promising antibiotic sensitizer, and can be used in combination with the polymyxin drug colistin to resist the colistin drug resistance problem of escherichia coli, salmonella and klebsiella pneumoniae.

The application discloses a red blood cell adhesion enhancer, wherein 1000 mL of the red blood cell adhesion enhancer comprises the following components: 0.5-2.0 g of sodium chloride, 2.0-5.0 g of disodium ethylenediaminetetraacetate, 1.0-3.0 g of sodium citrate, and the rest is ultrapure water. The red blood cell adhesion enhancer and the cell suspension of washed human packed red blood cells can be used for preparing a solid-phase agglutination reaction microplate. Compared with a traditional "normal saline-red blood cell" suspension, the cell suspension constructed by the red blood cell adhesion enhancer and the human packed red blood cells can significantly increase the number of red blood cells adhered to the surface of a solid-phase microplate carrier, ensure the sufficient and stable number of adhered red blood cell antigens in a long-term storage process of the solid-phase microplate, ensure the number of red blood cell antigens reacted with a to-be-tested antibody, improve the sensitivity of the solid-phase agglutination reaction, avoid false negatives caused by missed detection of the same antibody, and reduce the risk of blood transfusion.

The invention discloses an HRP chemiluminescent substrate system, a kit and a preparation method, the HRP chemiluminescent substrate system is composed of a liquid A and a liquid B which are physically isolated and stored; the solution A is an alkaline buffer system with the pH value of 9.0-9.6, and comprises isoluminol or a salt substrate thereof, a cationic surface active agent CTAC and a metal chelating agent diethylene triamine pentaacetic acid; and the solution B is an acidic solution with the pH value of 4.5-5.5, and comprises an oxidizing agent and a reinforcing agent N-(3-chloro-4-hydroxyphenyl) acetanilide. According to the invention, the reinforcing agent N-(3-chloro-4-hydroxyphenyl) acetanilide is placed in the acidic liquid B, when the acidic liquid B is mixed with the alkaline liquid A, the mixed system is maintained at a specific pH value of 8.3-8.6, and the reinforcing agent is rapidly dissociated into phenoxy anions; and carrying out in-situ capture and enrichment on a micelle interface by CTAC cationic micelles with positive charges, which exist in the solution A in advance, through electrostatic attraction. And in cooperation with a low-ion-strength environment brought by no buffer salt in the liquid B, the system ensures the high activity of the HRP enzyme, realizes directional interface catalysis of the enhancer, and significantly improves the luminous efficiency and stability.

The present invention concerns compositions comprising at least one niclosamide compound, such as niclosamide or a pharmaceutically acceptable salt thereof, and at least one permeability enhancer, such as glycerol or dimethylpalmityl-ammonio propanesulfonate (PPS), and their use of such compositions as niclosamide agents. Advantageously, the niclosamide compound is capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 cell membrane in the absence of the permeability enhancer. Compositions, including oral dosage forms, and methods for delivering niclosamide compounds, such as for treatment or prevention of human coronavirus infections, are also provided.

To provide an agent for treating pancreatic cancer.SOLUTION: An agent for treating pancreatic cancer comprising 1-kestose as an active ingredient.SELECTED DRAWING: Figure 1

The present application relates to viral sensitizers. More specifically, the present application relates to inhibitors of PDKP1, as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses and increasing transduction.

The invention discloses an immunogenic composition containing gE virus-like nanoparticles as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE virus-like nanoparticles comprise VZV gE, a linker peptide (SGS) and a VZV gI polypeptide containing a Th epitope. The immunogenic composition provided by the invention can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is better than that of Xinanliei, the use of an immunopotentiator is reduced, and the clinical side reaction is lower. In addition, the vaccine can also induce an obvious gI specific antibody, which is beneficial for further improving the effectiveness of the vaccine. In short, the immunogenic composition provided by the invention has good clinical application potential.

The application discloses application of ginsenoside Rf in preparation of an enhancer of a PD-1 inhibitor antitumor drug, and the ginsenoside Rf has the effects of improving a PD-1 inhibitor antitumor response rate, prolonging a survival period, and reducing toxicity, and has a significant advantage in enhancing PD-1 inhibitor treatment of tumors.

The invention belongs to the technical field of molecular biology, and provides a reinforcing agent for improving amplification efficiency of mismatched primers in PCR (polymerase chain reaction), a reaction system and application of the reinforcing agent. The reaction system is a liquid reaction system and comprises a reinforcing agent, Trisma, dNTP (deoxyribonucleoside triphosphate), MgCl2, NH4Cl, KCl, BSA (bovine serum albumin), glycerol, betaine, a specific primer, a DNA (deoxyribonucleic acid) template, DNA polymerase, DMSO (dimethylsulfoxide) and water. The invention also provides an application of the enhancer in gene polymorphism detection by a PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism) method. Tetramethylammonium chloride and glutathione in the enhancer have a synergistic effect, so that the binding capacity of a mismatched primer and a DNA template can be remarkably enhanced, the completeness of a mismatched region at the 3'end of the primer is protected, and non-specific amplification is inhibited while the amplification efficiency is improved.

This invention relates to the field of biomedical technology, specifically to a serum-free and protein-free culture medium and its preparation method for enhancing NK cell expansion and cytotoxic activity. The serum-free and protein-free culture medium comprises a basal medium, an AMPK-HIF1α regulator, immunomodulatory factors, mitochondrial function enhancers, antioxidants, trace elements, and a pH buffer. The AMPK-HIF1α regulator is composed of α-ketoglutarate at a final concentration of 1.4-1.6 mmol / L and AICAR at 0.4-0.6 mmol / L. This culture medium activates the AMPK-HIF1α pathway through precise formulation of α-ketoglutarate and AICAR, and optimizes the metabolic-antioxidant network in synergy with nicotinamide ribose and glutathione, thus solving the industry problem of the incompatibility between expansion and function in serum-free NK cell culture.